ASPEN PHAR.UN.ADR /1 O.N. (LDZU) — Cash Flow Reinvestment Rate
ASPEN PHAR.UN.ADR /1 O.N. (LDZU) has a Cash Flow Reinvestment Rate of 0.98x as of June 2025, reinvesting €5.05 Billion (capex €5.05 Billion ) from operating cash flow of €5.16 Billion. Check cash flow quality index of ASPEN PHAR.UN.ADR /1 O.N. to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
ASPEN PHAR.UN.ADR /1 O.N. Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for ASPEN PHAR.UN.ADR /1 O.N. across 4 annual periods. Explore ASPEN PHAR.UN.ADR /1 O.N. (LDZU) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
Year-by-year capital reinvestment analysis for ASPEN PHAR.UN.ADR /1 O.N.. For live market cap and broader valuation context, see market value of ASPEN PHAR.UN.ADR /1 O.N..
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.98x | €5.05 Billion | €5.16 Billion | €5.05 Billion | ▲ +10.2% |
| 2024 | 0.89x | €5.54 Billion | €6.22 Billion | €5.54 Billion | ▲ +54.3% |
| 2023 | 0.58x | €3.18 Billion | €5.52 Billion | €3.18 Billion | ▲ +11.1% |
| 2022 | 0.52x | €2.79 Billion | €5.37 Billion | €2.70 Billion | — |